According to Radu Rasinar, General Manager of Eli Lilly Romania, the new product could generate sales worth €6.4 - €12.8 million. The company will launch at least six products in the coming 2-3 years.
Eli Lilly expects turnover worth €38 mln this year, 10 percent higher than in 2007. The Romanian market has a 3-4 percent ratio of total sales for Europe.
The company claims some 20 percent of the local diabetes drug market share, which yields 25 percent of Eli Lilly’s turnover.
![[P] 35.000 de solicitări în șapte ani pentru sprijin în dependența de jocuri de noroc: 3 din 4 persoane care apelează Consilierea 24/7 cer consiliere psihologică](/_next/image?url=https%3A%2F%2Fmoney-ro-cdn.sorin-freciu.workers.dev%2Fstorage%2Fv1%2Fobject%2Fpublic%2Fmedia%2Farticles%2F1791483335473-zbeb97ppvr.jpg&w=1920&q=75)
